NBY Key Stats
|Revenue (Quarterly YoY Growth)||-69.82%|
|EPS Diluted (TTM)||-0.3942|
|EPS Diluted (Quarterly YoY Growth)|
|Net Income (TTM)||-14.26M|
|Gross Profit Margin (Quarterly)||96.09%|
|Profit Margin (Quarterly)||-350.1%|
|Dividend Yield (TTM)||0%|
|Payout Ratio (TTM) Pro||Go Pro|
- NovaBay Pharmaceuticals' NeutroPhase®: A New Adjunctive Therapy to Manage 'Flesh-Eating' Disease Accesswire 9:20 AM
- NVC-422 Gives NovaBay Huge Growth Potential 7:46 AM
- NovaBay Pharmaceuticals and China Pioneer Pharma Announce Expansion Of Partnershiup Agreement noodls Dec 2
- NovaBay Pharmaceuticals and China Pioneer Pharma Announce Expansion of Partnership Agreement GlobeNewswire Dec 2
- NOVABAY PHARMACEUTICALS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Eq Dec 2
- NovaBay Pharmaceuticals Announces Publication of Novel Surgical Procedure for Life Threatening Wounds and Flesh Eating Bacteria Business Wire Nov 19
- WallStreetCorner.Com Makes NovaBay Its Stock Pick in November Nov 15
- NovaBay Pharmaceuticals Reports Third Quarter 2013 Financial Results and a Clinical /Business Update noodls Nov 14
- NovaBay Pharmaceuticals Reports Third Quarter 2013 Financial Results and a Clinical/Business Update GlobeNewswire Nov 14
- NOVABAY PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report Nov 14
NBY Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). NovaBay Pharmaceuticals is up 21.05% over the last year vs S&P 500 Total Return up 30.67%, Acura Pharmaceuticals up 12.00%, and Takeda Pharmaceutical up 8.01%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Balance Sheet View Statement
Pro Ratings for NBY
Pro Strategies Featuring NBY
Did NovaBay Pharmaceuticals make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
NovaBay Pharmaceuticals, Inc., is a clinical-stage biotechnology company focused on addressing the large unmet therapeutic needs of the global anti-infective market.